Search research articles
Contact Us
Filters
Showing results (601-610 of 662) with videos related to
Page
of 67
Sort By:
Rofo : Fortschritte Auf Dem Gebiete Der Rontgenstrahlen Und Der Nuklearmedizin
|
November 4, 2024
Large language models (LLMs) in radiology exams for medical students: Performance and consequences
Jennifer Gotta, Quang Anh Le Hong, Vitali Koch, et al.
Cancer Treatment and Research Communications
|
November 18, 2023
Presentation and outcomes of KRAS<sup>G12C</sup> mutant non-small cell lung cancer patients with stage IV disease at diagnosis (de novo) versus at recurrence
Niki Esfahanian, Sze Wah Samuel Chan, Luna J Zhan, et al.
Nature Medicine
|
October 9, 2023
ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results
Valsamo Anagnostou, Cheryl Ho, Garth Nicholas, et al.
Current Oncology (Toronto, Ont.)
|
November 23, 2018
Canadian perspectives: update on inhibition of <i>ALK</i>-positive tumours in advanced non-small-cell lung cancer
B Melosky, P Cheema, J Agulnik, et al.
The Lancet. Oncology
|
December 10, 2016
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
Matthew D Hellmann, Naiyer A Rizvi, Jonathan W Goldman, et al.
Science (New York, N.Y.)
|
February 13, 2025
Computational design of serine hydrolases
Anna Lauko, Samuel J Pellock, Kiera H Sumida, et al.
Bioorganic & Medicinal Chemistry Letters
|
July 21, 2004
The development of novel inhibitors of tumor necrosis factor-alpha (TNF-alpha) production based on substituted [5,5]-bicyclic pyrazolones
Matthew J Laufersweiler, Todd A Brugel, Michael P Clark, et al.
Clinical Lung Cancer
|
October 1, 2016
Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations
Natasha B Leighl, Naiyer A Rizvi, Lopes Gilberto de Lima, et al.
ESMO Open
|
February 17, 2026
Fast Real-Time Assessment of Combination Therapies in Immuno-ONcology in patients with advanced non-small-cell lung cancer (FRACTION-Lung)
K He, P M Forde, R Govindan, et al.
Biorxiv : the Preprint Server for Biology
|
November 19, 2025
De novo design of RNA and nucleoprotein complexes
Andrew Favor, Riley Quijano, Elizaveta Chernova, et al.
Page
of 67
Search research articles
Search
Showing results (601-610 of 662) with videos related to
Sort By:
Page
of 67
Rofo : Fortschritte Auf Dem Gebiete Der Rontgenstrahlen Und Der Nuklearmedizin
|
November 4, 2024
Large language models (LLMs) in radiology exams for medical students: Performance and consequences
Jennifer Gotta, Quang Anh Le Hong, Vitali Koch, et al.
Cancer Treatment and Research Communications
|
November 18, 2023
Presentation and outcomes of KRAS<sup>G12C</sup> mutant non-small cell lung cancer patients with stage IV disease at diagnosis (de novo) versus at recurrence
Niki Esfahanian, Sze Wah Samuel Chan, Luna J Zhan, et al.
Nature Medicine
|
October 9, 2023
ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results
Valsamo Anagnostou, Cheryl Ho, Garth Nicholas, et al.
Current Oncology (Toronto, Ont.)
|
November 23, 2018
Canadian perspectives: update on inhibition of <i>ALK</i>-positive tumours in advanced non-small-cell lung cancer
B Melosky, P Cheema, J Agulnik, et al.
The Lancet. Oncology
|
December 10, 2016
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
Matthew D Hellmann, Naiyer A Rizvi, Jonathan W Goldman, et al.
Science (New York, N.Y.)
|
February 13, 2025
Computational design of serine hydrolases
Anna Lauko, Samuel J Pellock, Kiera H Sumida, et al.
Bioorganic & Medicinal Chemistry Letters
|
July 21, 2004
The development of novel inhibitors of tumor necrosis factor-alpha (TNF-alpha) production based on substituted [5,5]-bicyclic pyrazolones
Matthew J Laufersweiler, Todd A Brugel, Michael P Clark, et al.
Clinical Lung Cancer
|
October 1, 2016
Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations
Natasha B Leighl, Naiyer A Rizvi, Lopes Gilberto de Lima, et al.
ESMO Open
|
February 17, 2026
Fast Real-Time Assessment of Combination Therapies in Immuno-ONcology in patients with advanced non-small-cell lung cancer (FRACTION-Lung)
K He, P M Forde, R Govindan, et al.
Biorxiv : the Preprint Server for Biology
|
November 19, 2025
De novo design of RNA and nucleoprotein complexes
Andrew Favor, Riley Quijano, Elizaveta Chernova, et al.
Page
of 67